Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 184 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... April 22, 2021 Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for... February 4, 2025 News digest – dinosaur bone cancer, YouTube junk food ad ban... August 8, 2020 Do Cancer Survivors Have To Be Positive All the Time? Letting... November 10, 2021 Load more HOT NEWS Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... El cáncer en mi comunidad: Cómo superar las desigualdades en la... Alectinib Approved as an Adjuvant Treatment for Lung Cancer Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced
